Moderna (MRNA) Stock: Price, Trend, Options & Financials
Moderna's price regime, relative strength, unusual-options and unusual-volume history, curated-manager ownership and filed fundamentals — joined into one dated stock intelligence page.
What the evidence says now
MRNA closed at $145.07 on Aug 21, 2026. The price is +114.6% from its 50-day average and +197.7% from its 200-day average, which places it in the rules-based “established uptrend” regime. The relative-strength check: over three months the stock returned +207.0%, beating SPY by 203.9%. It remains 17.9% below its 52-week high.
Sources, methodology & freshnessLast updated 2026-08-21 · Open ↓Close ↑
The close is +114.6% from its 50-day average and +197.7% from its 200-day average. Over three months, MRNA returned +207.0% versus +3.1% for SPY.
- vs 50-day
- +114.6%
- vs 200-day
- +197.7%
- From 52W high
- -17.9%
Descriptive, not predictive. “Uptrend” is a rules-based reading of the close and moving averages; it is not a rating, price target or recommendation.
Price & regime
One year of daily price and volume
252 split-adjusted sessions · candles above, share volume below
Unusual options — attention, not intent
MRNA appeared in a UOA top-30 list on 4 of 62 archived scanner sessions: 3 call-side, 2 put-side and 1 on both lists. The latest session placed its call-side signature #4. Its larger composite score was 3.01, above the 1.5 “strong” threshold. That is repeated options attention, not proof of bullish trade initiation.
| Recent flag | Call rank | Put rank |
|---|---|---|
| 2026-08-21 | #4 | — |
| 2026-08-20 | #3 | #6 |
| 2026-08-19 | — | #8 |
| 2026-07-10 | #16 | — |
Latest chain snapshot
2026-08-21Strong-signature cutoff: 1.5. Current OTM volume/OI: 2.645 calls, 0.409 puts.
Researched catalyst context
2026-08-21Aug 21: +8.8% on about 5.9 times normal volume, a third session of follow-through from the Aug 19 Phase 3 readout of the Moderna–Merck individualized mRNA melanoma therapy. The trial met its recurrence-free-survival endpoint and a key distant-metastasis-free-survival endpoint; there was no new company release Friday.
Moderna rose 177% on the readout day as the market repriced the oncology platform rather than the COVID franchise. This was a topline result, not an approval or a full data presentation: the companies plan to present detailed efficacy and safety results at a future medical meeting and discuss them with regulators. The next durable checkpoints are the full dataset and the regulatory path; until then, a three-session move of this size can remain unusually volatile.
Source: Merck and Moderna: Phase 3 INTerpath-001 topline results ↗Curated-manager ownership
1 of the 20 managers in the project's curated 13F set reported a long Moderna position in their latest filing, worth $139M in aggregate at each filing's reported value. This is a focused manager panel, not the complete institutional holder list.
| Fund / manager | Position value | Portfolio | Shares | Quarter change | Report date |
|---|---|---|---|---|---|
Baron Capital Group Ron Baron · MRNA | $139M | 0.21% | 1.99M | — new | 2026-06-30 |
Filed fundamentals — latest snapshot
Go deeper into the filings
The dedicated Financials dashboard carries the complete quarterly and annual income statement, balance sheet and cash-flow history, with derived figures flagged and every XBRL concept disclosed.
Open MRNA Financials →How MRNA trades — the working manual
Moderna develops and commercializes medicines built on its messenger-RNA platform, with respiratory vaccines funding a broader pipeline in oncology, latent and public-health vaccines, and rare diseases. For the stock, commercial vaccine demand and cash use matter alongside probability-weighted clinical and regulatory milestones: one successful program can change the platform's perceived value well before it contributes revenue.
What can move the tape
- 01Commercial demand, market share and seasonality across the COVID and RSV vaccine franchises.
- 02Clinical evidence, regulatory timing and economics for intismeran autogene and the broader oncology pipeline.
- 03Progress across influenza, combination respiratory, latent-virus and rare-disease programs.
- 04Research spending, manufacturing utilization and the pace at which cash and investments fund the pipeline.
What can fool the read
- 01Vaccine recommendations, market acceptance and seasonal demand can change faster than manufacturing commitments.
- 02Topline trial success is not approval; detailed efficacy, safety and regulatory review can change the commercial outcome.
- 03Pipeline value is concentrated in uncertain clinical milestones while the company continues to report operating losses.
- 04Large event-driven moves can overwhelm moving-average and options signals until the price establishes a new range.
Moderna triggered 8 issuer-level flags in the committed 2026-04-01–2026-08-21 archive. The latest was MRNA on 2026-08-21: 5.9× its 30-day average volume while the stock moved +9.0% that session.
Not published yet. The local archive has 1 reported MRNA events—too few for a defensible gap-and-drift study. This missing block is an explicit indexing blocker.
Source map & freshness
| Block | What it uses | Vintage | Raw data |
|---|---|---|---|
| Identity | SEC issuer + primary security mapping | 2026-08-23 | JSON ↓ |
| Price & trend | Split-adjusted daily OHLCV + SPY comparison | 2026-08-21 | CSV ↓ |
| Options | End-of-day chain anomaly ranks | 2026-08-21 | Premium → |
| Ownership | Latest filings from 20 curated 13F managers | 2026-08-21 | Tool → |
| Financials | SEC EDGAR XBRL company facts | 2026-08-21 | JSON ↓ |
| Joined profile | The exact contract rendered by this page | 2026-08-23 | JSON ↓ |
MRNA stock questions
Is MRNA stock in an uptrend?+
MRNA is classified in the “established uptrend” regime as of 2026-08-21: the close is +114.6% from its 50-day average and +197.7% from its 200-day average. This describes the current tape. It is not a forecast.
What does unusual options activity in MRNA mean?+
Moderna's OTM option chain produced an outlier relative to the scanner universe on at least one archived session. Call-side and put-side labels identify which book produced the signature; end-of-day chain data does not identify buyers, sellers, institutions or spread legs.
Are the MRNA 13F holdings current?+
No. 13F filings are delayed quarter-end snapshots and cover only the curated managers in this project. They are useful for documented ownership changes, not real-time positioning or complete institutional ownership.
Where are MRNA's income statement and cash flow?+
The dedicated MRNA Financials page contains the full quarterly and annual income statement, balance sheet and cash-flow history parsed from SEC EDGAR XBRL. This stock page carries only the latest filed snapshot.
Why is there no MRNA earnings-move base rate yet?+
The committed earnings archive does not yet contain enough reported events for a defensible company-level reaction study. The page leaves that block unpublished instead of presenting a tiny sample as a reliable base rate.